2GH Stock Overview
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Merus N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$38.00 |
| 52 Week High | US$48.60 |
| 52 Week Low | US$16.40 |
| Beta | 1.11 |
| 1 Month Change | -5.94% |
| 3 Month Change | 31.94% |
| 1 Year Change | 98.95% |
| 3 Year Change | 101.06% |
| 5 Year Change | 148.37% |
| Change since IPO | 168.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2GH | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.5% | -4.9% | -1.5% |
| 1Y | 99.0% | -19.9% | 0.9% |
Return vs Industry: 2GH exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: 2GH exceeded the German Market which returned -0.4% over the past year.
Price Volatility
| 2GH volatility | |
|---|---|
| 2GH Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2GH's share price has been volatile over the past 3 months.
Volatility Over Time: 2GH's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 201 | Bill Lundberg | www.merus.nl |
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.
Merus N.V. Fundamentals Summary
| 2GH fundamental statistics | |
|---|---|
| Market cap | €2.26b |
| Earnings (TTM) | -€145.57m |
| Revenue (TTM) | €41.29m |
54.8x
P/S Ratio-15.5x
P/E RatioIs 2GH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2GH income statement (TTM) | |
|---|---|
| Revenue | US$43.95m |
| Cost of Revenue | US$140.66m |
| Gross Profit | -US$96.71m |
| Other Expenses | US$58.23m |
| Earnings | -US$154.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.64 |
| Gross Margin | -220.06% |
| Net Profit Margin | -352.56% |
| Debt/Equity Ratio | 0% |
How did 2GH perform over the long term?
See historical performance and comparison